Pacira BioSciences, Inc. (PCRX) Earnings Call Analysis
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Next earnings call: 2026-08-04
(Q2 2026)
— full calendar
Earnings Reports
-
PACIRA (PCRX) Q1 2026: Expirel Volume Grows 7% as 5x30 Strategy Drives Durable Franchise Momentum
May 01, 2026
-
PACIRA (PCRX) Q4 2025: 102M Covered Lives Drive XBRL Access Surge, Margin Expansion On Track
February 27, 2026
-
Pacira Biosciences (PCRX) Q3 2025: Expirel Volumes Up 9% as GPO Strategy Drives Market Penetration
November 10, 2025
-
PCRX Q2 2025: Gross Margin Rises to 82% as Manufacturing Efficiencies Accelerate
August 06, 2025
-
Pacira Biosciences (PCRX) Q1 2025: Xpirel Volume Up 7% as No Pain Reimbursement Drives Early Uptake
July 05, 2025